Gapping up
In reaction to strong earnings/guidance: OMN +29.9%, APRI +17.6%, STZ+2.8%, (also to acquire The Prisoner Wine Company's portfolio of brands from Huneeus Vintners) GPN +1.7%
M&A news: PLCM +8.4% (Bloomberg reports Co is in advanced merger talks with MITL), PFE +1.1% (Pfizer confirms its and Allergan (AGN) will terminate their planned merger), AMZN +0.6% (acquired AI startup Orbeus, according to Bloomberg)
Select Large pharma related names showing strength: AZN +2.3%, SHPG+2.1%, GSK +0.9%
Select oil/gas related names showing strength: WLL +4%, CHK +3.7%, SWN+3.2%, RIG +2.2%, RIG +2.1%, MRO +1.8%, CVX +0.9%, XOM +0.7%
Other news: SUNE +30.4% (cont vol pre-mkt), TSRO +5.7% (Tesaro and Janssen Biotech, a Johnson & Johnson (JNJ) unit, announce collaboration and license agreement focused on the development and commercialization of niraparib specifically for the treatment of prostate cancer), OAS +3.6% (commences an open season for the Johnson's Corner Pipeline Project),LINE +3.2% (enters into settlement agreement with certain debt holders),AYI +1.8% (following CREE results; AYI reports tomm), NOK +1.7% (begins restructuring, job cuts), LGIH +1.5% (reported March closing +23 YoY),KMDA +1.3% (initiates phase 2 clinical trial with intravenous alpha-1 antitrypsin for the prevention of lung transplant rejection)
Analyst comments: SRPT +7.5% (target raised to $60 from $45 at Oppenheimer ), CDK +1.5% (upgraded to Neutral from Underweight at JP Morgan), CSCO +1.2% (upgraded to Neutral from Underweight at JP Morgan), CELG +0.8% (initiated with Outperform ratings at BMO Capital),AAPL +0.7% (initiated with a Strong Buy at Needham)
In reaction to strong earnings/guidance: OMN +29.9%, APRI +17.6%, STZ+2.8%, (also to acquire The Prisoner Wine Company's portfolio of brands from Huneeus Vintners) GPN +1.7%
M&A news: PLCM +8.4% (Bloomberg reports Co is in advanced merger talks with MITL), PFE +1.1% (Pfizer confirms its and Allergan (AGN) will terminate their planned merger), AMZN +0.6% (acquired AI startup Orbeus, according to Bloomberg)
Select Large pharma related names showing strength: AZN +2.3%, SHPG+2.1%, GSK +0.9%
Select oil/gas related names showing strength: WLL +4%, CHK +3.7%, SWN+3.2%, RIG +2.2%, RIG +2.1%, MRO +1.8%, CVX +0.9%, XOM +0.7%
Other news: SUNE +30.4% (cont vol pre-mkt), TSRO +5.7% (Tesaro and Janssen Biotech, a Johnson & Johnson (JNJ) unit, announce collaboration and license agreement focused on the development and commercialization of niraparib specifically for the treatment of prostate cancer), OAS +3.6% (commences an open season for the Johnson's Corner Pipeline Project),LINE +3.2% (enters into settlement agreement with certain debt holders),AYI +1.8% (following CREE results; AYI reports tomm), NOK +1.7% (begins restructuring, job cuts), LGIH +1.5% (reported March closing +23 YoY),KMDA +1.3% (initiates phase 2 clinical trial with intravenous alpha-1 antitrypsin for the prevention of lung transplant rejection)
Analyst comments: SRPT +7.5% (target raised to $60 from $45 at Oppenheimer ), CDK +1.5% (upgraded to Neutral from Underweight at JP Morgan), CSCO +1.2% (upgraded to Neutral from Underweight at JP Morgan), CELG +0.8% (initiated with Outperform ratings at BMO Capital),AAPL +0.7% (initiated with a Strong Buy at Needham)